Turbine’s Post

How does CHARMED from Sygnature Discovery work in action? Using the clinically relevant oncology target SHP2 in the Ras pathway as a model, we showcase our capabilities in degrader synthesis and the development of high-quality in vitro assays for compound profiling. We demonstrate this through a customer project, where potent degraders were swiftly identified.   Learn more from Dr Steve Young (VP of Business Development) and Dr Hiroki Wada (Business Development Manager) at the poster presentation at EFMC-ACSMEDI MedChem Frontiers in Utrecht, April 8-11. Can’t make the event? Download our digital poster: https://lnkd.in/eN3iQ68U #medicinalchemistry #CHARMED #targetedproteindegradation #drugdiscovery

Wonder what we are up to at MOMA? We are focused on highly dynamic proteins. Learn more below

Next month, our own Philipp Pauli, Country Head Germany, will host the Big Data in Oncology panel discussion during the BioTechX EU conference on October 9th in Basel, Switzerland. Want to hear Philipp’s thoughts on big data and the latest in multiomic data management and personalized therapies ahead of the conference? Read his interview here: https://lnkd.in/e6CUHjeZ #BioTechX #BigDataInOncology

The dynamic needs of your preclinical and translational studies require innovative technologies grounded in science, driven by data. Our end-to-end services use the most advanced analysis and generate comprehensive data, utilizing machine intelligence to help you make better-informed decisions. ✅OrganoidXploreᵀᴹ is our large-scale organoid panel screening platform providing robust, reproducible, and clinically relevant results. ✅SynAI is our AI-driven platform designed to predict the synergistic effects of cancer drug combinations, trained with over 1.2 million in vitro tests. ✅Our global CRISPR licenses cover an integrated drug discovery platform for in vitro and in vivo efficacy studies, with seamless delivery.  ✅We provide certified CRO services using NanoString's GeoMx® platform to efficiently address tissue diversity and intricate micro-environments. Learn more➡️ https://hubs.la/Q02WPT0L0

Every company out there offers "integrated solutions" but what does that mean? What does that get you? It is not about piecing services together like a puzzle; it's about a tailored, data driven approach that provides insight to your unique molecule. ` This is drug discovery. There is no roadmap. Integration won't get you there. You need translation. # don't integrate translate #removetheguessework #dontintegragetranslate

Ever wish your data could predict the future? Check out our new site and video to see how we’re turning oncology guesswork into science! https://hubs.la/Q02XvDTV0 #Oncology #DrugDiscovery #personalizedmedacine #PredictiveScience #Innovation #preclinicalsolutions

Imagine if your scientific data provided the full picture - so you could make faster, actionable and more predictive decisions... Check out our NEW website homepage and watch the short video below to learn how we are removing the guesswork involved with oncology drug discovery and development 🎯 https://lnkd.in/eYrEqqqa

I am excited to share the publication of our research paper in RSC Lab on a Chip titled "Selectively cross-linked hydrogel-based cocktail drug delivery micro-chip for colon cancer combinatorial drug screening using AI-CSR platform for precision medicine". In this study, we demonstrated a selectively cross-linked hydrogel-based microfluidic platform that can quantify and release drugs simultaneously, promising to be a faster, efficient and more precise approach for conducting cocktail drug screening experiments. The integration of an artificial intelligence-based complex system response (AI-CSR) platform successfully identifies optimal drug-dose combinations from a pool of ten approved drugs. https://lnkd.in/gucGauds

If you're in Boston on Dec 10-12, come listen to Chuhern Hwang at Wayfinder Biosciences talk about how to use novel RNA binders for drug discovery!

#AI #Pharma It's not that I do not appreciate the buzz around LLMs. They are absolutely cool - just check out the recent (open-sourced!) Llama 3.1 released my Meta just a few day ago. And yes, there's a lot of cross-pollination happening between different sectors and domains in AI. But what really keeps me motivated, working, studying, and training around the clock are somewhat different kind of stories - from the healthcare, pharmaceuticals, chemistry. Take a moment to explore what the folks from Leash Bio are doing right now. There's so much hidden value, impact, and life-changing potential here! If I were running a VC fund these days - I'd definitely go into this kind of ventures...